ARGENICA THERAPEUTICS LIMITED. The +10 year research on ARG-007 and recent IPO might be more important in the future than we are currently projecting im our future market size potential. Research data projects the market potential at $183 billion by 2030 to treat stroke patients. However, this figure does not consider the effects of long covid.
A recent analysis of the health records of more than 230,000 people with COVID-19 found that around one-third experienced a neurological or psychiatric condition up to six months after infection.Roughly 13 per cent of those patients had not been diagnosed with those types of conditions previously.
How does COVID-19 actually affect the brain?
In the early days of the pandemic, researchers wondered whether the SARS-CoV-2 virus could break into the brain and infect neurons, the cells that send and receive information.But most studies have failed to track down the virus hiding out in the brain.
For instance, a recent US study that analysed brain tissue from eight patients who died from COVID-19 found no traces of the virus in the samples.
But the research did find more signs of inflammation in the brain tissue of COVID-19 patients than the control group, suggesting that inflammatory responses triggered by the virus in other parts of the body can kickstart inflammation in the brain.
Tissa Wijeratne, a neurologist at the University of Melbourne, has also found inflammatory markers linked with the immune response in the blood of patients who experience neurological issues months after they were first infected with the virus.
“The virus doesn't have to go to the brain to make an impact,” said Professor Wijeratne, who is currently investigating the long-term neurological effects of COVID-19.
A recent international survey of more than 3,700 hospitalised COVID-19 patients found 82 per cent had neurological symptoms.
Headaches and loss of taste or smell were the most common symptoms patients reported, while coma and strokes were the most frequent neurological abnormalities bedside clinicians saw in their patients.
- Forums
- ASX - By Stock
- AGN
- ARGENICA THERAPEUTICS LIMITED IPO Analysis
ARGENICA THERAPEUTICS LIMITED IPO Analysis, page-85
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AGN (ASX) to my watchlist
|
|||||
Last
79.0¢ |
Change
0.010(1.28%) |
Mkt cap ! $100.4M |
Open | High | Low | Value | Volume |
78.0¢ | 80.0¢ | 78.0¢ | $12.31K | 15.64K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 2093 | 79.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
83.0¢ | 14798 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 2093 | 0.790 |
1 | 65789 | 0.785 |
1 | 3439 | 0.780 |
2 | 30844 | 0.775 |
3 | 77341 | 0.770 |
Price($) | Vol. | No. |
---|---|---|
0.830 | 14798 | 3 |
0.835 | 650 | 1 |
0.840 | 3571 | 1 |
0.850 | 620 | 1 |
0.870 | 13668 | 2 |
Last trade - 15.48pm 30/08/2024 (20 minute delay) ? |
Featured News
AGN (ASX) Chart |
The Watchlist
CCO
THE CALMER CO INTERNATIONAL LIMITED
Anthony Noble, MD & CEO
Anthony Noble
MD & CEO
Previous Video
Next Video
SPONSORED BY The Market Online